Drug intelligence / Profile preview

VBX-3500

Development stage: Preclinical
Lead developer: Vetbiolix
Modality: Small Molecules
Administration: Oral

Overview

VBX-3500 is a small molecule 5-HT4 receptor agonist being developed by Vetbiolix for the treatment of gastrointestinal motility disorders in cats. As a prokinetic agent, it stimulates motility throughout the gastrointestinal tract by targeting 5-HT4 receptors. The drug is part of a broader development program (VBX-3000) involving molecules licensed from human biotechnology companies for veterinary use. VBX-3500 is specifically positioned for feline indications, such as feline coprostasis, and is currently undergoing clinical proof of concept studies.

Targets

HTR4 (5-Hydroxytryptamine receptor 4)

Beyond the preview

Go deeper on VBX-3500.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VBX-3500.

Explore the full profile